x
CME-Tagline

Live Q&A: Advances in Amyotrophic Lateral Sclerosis: The Role of Genetic Testing and Emerging Therapies

CMEO Webcast

Premiere Date: Wednesday, June 8, 2022

This activity will offer CE credit for:

  1. Medicine (accme)
  2. Nursing (ANCC)
  3. Pharmacy (acpe)
  4. PA (aapa)

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date: Thursday, June 8, 2023

Faculty


Jinsy A. Andrews, MD, MSc, FAAN Jinsy A. Andrews, MD, MSc, FAAN (Moderator)
Director of Neuromuscular Clinical Trials, Department of Neurology
Columbia University Irving Medical Center
New York, NY

Ammar Al-Chalabi, PhD, FRCP, DipStat Ammar Al-Chalabi, PhD, FRCP, DipStat 
Professor of Neurology and Complex Disease Genetics
NIHR Senior Investigator
King's College London
London, UK

John C. Novak, MS, MD John C. Novak, MS, MD 
OhioHealth Neurological Physicians
Director, OhioHealth ALS Clinic
Westerville, OH

Jeremy M. Shefner, MD, PhD Jeremy M. Shefner, MD, PhD 
Professor and Chair of Neurology
Barrow Neurological Institute
Phoenix, AZ

Statement of Need

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative motor neuron disease that leads to paralysis of muscles required to move, speak, and breathe. Despite the impact of ALS on patients’ quality of life (QoL), a number of barriers to care continue to exist. Patients often go through multiple physicians and alternative diagnoses before presenting to ALS clinics with significant disability. Genetic testing can provide diagnostic support, prognostic information, and eligibility for participation in clinical trials of emerging therapies; However, there is little consensus on how and when to employ genetic testing or access promising treatments in development.

This live Q&A session is your opportunity to ask questions based on the CMEO Snack series that focused on recognizing diagnostic challenges in ALS, utilizing genetic testing, and assessing the safety and efficacy of emerging ALS agents.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Recognize the challenges in diagnosing ALS.
  • Employ genetic testing in patients with ALS based on the knowledge of genetic pathophysiology of ALS.
  • Assess safety and efficacy of emerging agents.

Financial Support

Supported by an educational grant from Biogen MA, Inc.

Target Audience

Adult neurologists, geneticists, genetic counselors, primary care physicians, PAs, nurse practitioners, nurses, physical therapists, occupational therapists, otolaryngologists

Credit Information

Specific CE Credit information is not available at this time. Please check again soon!

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Andrews reports the following financial relationships:

Consultant: AL-S Pharma AG; Amylyx Pharmaceuticals Inc.; Biogen Idec; Cytokinetics; Denali Therapeutics; Neurosense Therapeutics; Orphazyme; and Wave Life Sciences

Research Support: Alexion Pharmaceuticals, Inc.;AZTherapies Inc.; Biogen Idec; Biohaven Pharmaceuticals; Clene Nanomedicine, Inc.; Cytokinetics; Healey Center at Massachusetts General Hospital; National Institutes of Health; Novartis AG; Orion; and Ra Pharmaceuticals, Inc.

Dr. Al-Chalabi reports the following financial relationships:

Consultant: (All paid to his institution) Amylyx; Apellis Pharmaceuticals, Inc.; Biogen; BrainStorm Cell Therapeutics, Inc.; Cytokinetics, Inc.; GlaxoSmithKline; Lilly; Mitsubishi Tanabe Pharma Corporation; Novartis; Orion Pharma; QurAlis Corporation; and Wave Life Sciences

Speakers Bureau: (paid to his institution) Biogen and Cytokinetics, Inc.

Dr. Novak reports the following financial relationships:

Consultant: Amylyx Pharmaceuticals, Inc. and BridgeBio Pharma, Inc.

Grants: ALS Association

Speakers Bureau: Argenx and Amylyx Pharmaceuticals, Inc.

Dr. Shefner reports the following financial relationships:

Consultant: Amylyx; ApicBio; NeuroSense Therapeutics; Cytokinetics Incorporated; Denali Therapeutics; EMD Serono; GlaxoSmithKline; Helixmith; Mitsubishi Tanabe Pharma America; Novartis; Orphazyme; Orthogonal Therapeutics; Pinteon; RRD; Sanofi; and SwanBio Therapeutics, Inc.

Grants: National Institutes of Health (NIH); ALS Association; and Mitsubishi Tanabe Pharma America

Research Support: Alector, Inc.; Alexion Pharmaceuticals, Inc.; Amylyx; Biogen; Biotie Therapies (now Acorda Therapeutics); Cytokinetics Incorporated, Inc.; Ionis Pharmaceuticals; MediciNova, Inc.; Mitsubishi Tanabe Pharma America; and Orphazyme

The following peer reviewer and CME Outfitters staff have no financial relationships to disclose:

  • Jeffrey Helfand, DO (peer reviewer)
  • Kellie Busby, PharmD (planning committee)
  • Evan Luberger (planning committee)
  • Susan H Yarbrough, CHCP (planning committee)
  • Sharon Tordoff (planning committee)


  • Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

    Questions about this activity? Call us at 877.CME.PROS (877.263.7767).


    This document was last modified on:

    SNQ-151-060822-29